JP7214191B2 - Stem cell undifferentiated state maintenance agent and growth promoter - Google Patents
Stem cell undifferentiated state maintenance agent and growth promoter Download PDFInfo
- Publication number
- JP7214191B2 JP7214191B2 JP2018225425A JP2018225425A JP7214191B2 JP 7214191 B2 JP7214191 B2 JP 7214191B2 JP 2018225425 A JP2018225425 A JP 2018225425A JP 2018225425 A JP2018225425 A JP 2018225425A JP 7214191 B2 JP7214191 B2 JP 7214191B2
- Authority
- JP
- Japan
- Prior art keywords
- stem cells
- extract
- undifferentiated state
- agent
- japanese pepper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 207
- 239000003795 chemical substances by application Substances 0.000 title claims description 71
- 238000012423 maintenance Methods 0.000 title description 3
- 239000007952 growth promoter Substances 0.000 title 1
- 244000131415 Zanthoxylum piperitum Species 0.000 claims description 78
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 claims description 78
- 239000000284 extract Substances 0.000 claims description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 210000003780 hair follicle Anatomy 0.000 claims description 41
- 230000001737 promoting effect Effects 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 35
- 230000035755 proliferation Effects 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 238000012258 culturing Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 18
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 18
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 18
- 239000000469 ethanolic extract Substances 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 41
- 230000000694 effects Effects 0.000 description 36
- 239000002609 medium Substances 0.000 description 28
- 241000949456 Zanthoxylum Species 0.000 description 26
- 235000013305 food Nutrition 0.000 description 26
- 239000003814 drug Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 201000004384 Alopecia Diseases 0.000 description 21
- 241000219095 Vitis Species 0.000 description 16
- 230000001172 regenerating effect Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 231100000360 alopecia Toxicity 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229940116257 pepper extract Drugs 0.000 description 11
- -1 ethanol Chemical compound 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 230000003813 thin hair Effects 0.000 description 6
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 description 5
- 101710183392 Keratin, type I cytoskeletal 15 Proteins 0.000 description 5
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 230000003796 beauty Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 101150100611 KRT15 gene Proteins 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 241001093501 Rutaceae Species 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 210000001988 somatic stem cell Anatomy 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000002271 trichotillomania Diseases 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241001079064 Zanthoxylum schinifolium Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本発明は、幹細胞の未分化状態維持剤及び増殖促進剤、並びに幹細胞の未分化状態維持方法及び増殖促進方法に関する。 TECHNICAL FIELD The present invention relates to an agent for maintaining an undifferentiated state of stem cells, an agent for promoting proliferation of stem cells, and a method for maintaining an undifferentiated state of stem cells and a method for promoting proliferation of stem cells.
脊椎動物(特に哺乳動物)の組織は、傷害若しくは疾患、又は加齢等に伴い細胞・臓器の損傷が起こった場合、再生系が働き、細胞・臓器の損傷を回復しようとする。この作用に、当該組織に備わる幹細胞(組織幹細胞、体性幹細胞、成体幹細胞)が大きな役割を果たしている。幹細胞は、あらゆる細胞・臓器に分化する多能性を有しており、この性質により細胞・臓器の損傷部を補うことで回復に導くと考えられている。このような幹細胞を応用した、次世代の医療である再生医療に期待が集まっている。 In the tissues of vertebrates (particularly mammals), when cells/organs are damaged due to injury, disease, aging, or the like, the regeneration system works to recover the damaged cells/organs. Stem cells (tissue stem cells, somatic stem cells, adult stem cells) provided in the tissue play a major role in this action. Stem cells have pluripotency to differentiate into all kinds of cells and organs, and it is believed that this property leads to recovery by supplementing damaged parts of cells and organs. Expectations are high for regenerative medicine, which is a next-generation medical treatment that applies such stem cells.
哺乳動物における幹細胞研究で最も進んでいる組織は骨髄である。骨髄には生体の造血幹細胞が存在しており、全ての血液細胞再生の源であることが明らかにされた。さらに骨髄には、造血幹細胞とは別に、臓器や組織(例えば、骨、軟骨、筋肉、脂肪等)へ分化可能な幹細胞が包含されていることが報告されている(非特許文献1参照)。 The most advanced tissue for stem cell research in mammals is the bone marrow. Bone marrow contains the body's hematopoietic stem cells and has been shown to be the source of all blood cell regeneration. Furthermore, bone marrow is reported to contain stem cells capable of differentiating into organs and tissues (e.g., bone, cartilage, muscle, fat, etc.) in addition to hematopoietic stem cells (see Non-Patent Document 1).
さらに、近年、骨髄以外にも、皮膚、肝臓、膵臓、脂肪等、あらゆる臓器や組織に幹細胞が存在することが明らかにされ、各臓器や組織の再生及び恒常性維持を司っていることがわかってきた(非特許文献2~5参照)。また、各臓器や組織に存在する幹細胞は可塑性に優れており、今まで自己複製が不可能であった臓器や組織の再生にも利用できる可能性がある。 Furthermore, in recent years, it has been clarified that stem cells exist in all organs and tissues other than bone marrow, such as skin, liver, pancreas, and fat, and are responsible for the regeneration and maintenance of homeostasis of each organ and tissue. I have come to understand (see Non-Patent Documents 2 to 5). In addition, stem cells present in each organ and tissue have excellent plasticity, and may be used to regenerate organs and tissues that have been unable to self-renew until now.
一方で、これらの幹細胞のうちのいくつかは、加齢とともに減少することが知られており、各組織の恒常性維持のために幹細胞の減少を防ぐ技術の研究が積極的になされている(非特許文献6)。また、近年、幹細胞の能力(多能性)を、臓器や組織の再生へ応用するため、細胞移植治療や組織工学(再生医療や再生美容)の分野において幹細胞を生体組織から分離した後に培養し増殖させる技術の開発が進められている(非特許文献7、8)。 On the other hand, some of these stem cells are known to decrease with age, and research is being actively conducted on techniques to prevent the decrease of stem cells in order to maintain the homeostasis of each tissue ( Non-Patent Document 6). In recent years, in order to apply the ability (pluripotency) of stem cells to the regeneration of organs and tissues, in the fields of cell transplantation therapy and tissue engineering (regenerative medicine and regenerative beauty), stem cells are isolated from living tissues and then cultured. Techniques for proliferation are being developed (Non-Patent Documents 7 and 8).
特に、幹細胞を生体外で培養する場合、幹細胞の能力である多能性を維持した状態、すなわち、未分化な状態を維持させたまま増殖させることが極めて重要である。もし、この培養時に幹細胞の未分化状態が維持できず分化誘導が進んでしまった場合、最終的に調製された幹細胞の能力(多能性)は失われていることになり、目的の効果(臓器や組織の再生等)を発揮できない。 In particular, when stem cells are cultured in vitro, it is extremely important to proliferate them while maintaining their pluripotency, which is the ability of stem cells, that is, maintaining their undifferentiated state. If the undifferentiated state of the stem cells cannot be maintained during this culture and the induction of differentiation proceeds, the ability (pluripotency) of the finally prepared stem cells will be lost, resulting in the desired effect ( Regeneration of organs and tissues, etc.) cannot be demonstrated.
以上より、幹細胞を細胞移植治療や組織工学(再生医療や再生美容)に利用し、臓器や組織の再生を望む場合、幹細胞を、未分化状態を維持させたまま培養できなければならない。 Based on the above, when stem cells are used for cell transplantation therapy and tissue engineering (regenerative medicine and regenerative cosmetics) to regenerate organs and tissues, stem cells must be cultured while maintaining their undifferentiated state.
現在までに、幹細胞を、未分化状態を維持させたまま増殖させる技術について、幾つか報告があるが、未だ発展途上である。例えば、胚性幹細胞(ES細胞)や造血幹細胞は、支持細胞(ストローマ細胞、又はフィーダー細胞)と共培養することで未分化を維持することができる(特許文献1及び非特許文献9~11参照)。しかしながら、最近になってフィーダー細胞由来の内在性ウイルスによる異種動物間の感染例が報告されており(非特許文献12参照)、支持細胞を使用した幹細胞の培養は、医療用途を目的とした幹細胞の培養には適していない。 To date, there have been several reports on techniques for growing stem cells while maintaining their undifferentiated state, but they are still under development. For example, embryonic stem cells (ES cells) and hematopoietic stem cells can be maintained undifferentiated by co-culturing with supporting cells (stromal cells or feeder cells) (see Patent Document 1 and Non-Patent Documents 9-11). ). However, recently, cases of infection between heterologous animals by endogenous viruses derived from feeder cells have been reported (see Non-Patent Document 12), and culturing of stem cells using feeder cells has been proposed for medical purposes. not suitable for culturing
その他の方法に、サイトカインを複雑に組合せることによって幹細胞の未分化状態を維持させる方法がある。例えば、マウスES細胞は、LIF(白血病抑制因子(Leukemia Inhibitory Factor))を培地に添加することによって、未分化性が維持される(特許文献2及び非特許文献13参照)。その他、初期作用性サイトカイントロンボポイエチン(TPO)、インターロイキン6(IL-6)、FLT-3リガンド、及び幹細胞因子(SCF)の存在下で、未分化性を維持させることが胚性幹細胞、体性幹細胞等で報告されている(特許文献3及び非特許文献14参照)。 Another method is to maintain the undifferentiated state of stem cells by complex combinations of cytokines. For example, mouse ES cells are maintained undifferentiated by adding LIF (Leukemia Inhibitory Factor) to the medium (see Patent Document 2 and Non-Patent Document 13). Other embryonic stem cells that remain undifferentiated in the presence of early-acting cytokines thrombopoietin (TPO), interleukin-6 (IL-6), FLT-3 ligand, and stem cell factor (SCF); It has been reported in somatic stem cells and the like (see Patent Document 3 and Non-Patent Document 14).
しかしながら、サイトカインは、高価であり、採取原料や保存性等の問題があり、容易な使用は難しい。加えて、LIFの効果は極めて特定の細胞系統に限定的であり、特に霊長類のES細胞や体性幹細胞においては、LIFの添加のみでは未分化状態を維持することができないことが明らかにされている(非特許文献10参照)。 Cytokines, however, are expensive, and have problems such as collection raw materials and storage stability, and are difficult to use easily. In addition, it was revealed that the effect of LIF is limited to a very specific cell lineage, and that the undifferentiated state cannot be maintained especially in primate ES cells and somatic stem cells by the addition of LIF alone. (See Non-Patent Document 10).
このように、現在、報告されている幹細胞の未分化状態の維持方法はいずれも、煩雑な操作を必要とし、また未分化状態の維持効果が低い。従って、幹細胞を再生医療に利用するために、幹細胞を、未分化状態を維持したまま増殖させる技術が求められていた。つまり、安全且つ簡便で効率的に、幹細胞を、未分化状態を維持させたまま増殖させることができる技術が求められていた。 As described above, all of the currently reported methods for maintaining an undifferentiated state of stem cells require complicated operations and are less effective in maintaining an undifferentiated state. Therefore, in order to utilize stem cells in regenerative medicine, a technique for growing stem cells while maintaining an undifferentiated state has been desired. In other words, there has been a demand for a technology that can safely, simply, and efficiently proliferate stem cells while maintaining their undifferentiated state.
サンショウ(山椒、学名:Zanthoxylum piperitum)は、ミカン科サンショウ属の落葉低木で、その成熟した果皮や未熟な果実は香辛料として利用されている。また、生薬の山椒(サンショウ)は、成熟した果皮からできるだけ種子を除いたもので、サンショオールなどの成分を含み、健胃、鎮痛、利尿、駆虫作用等を有することから、消化不良、冷えによる腹痛、膨満感等を改善して胃腸の働きを高めるための漢方薬に用いられている。これまでサンショウには、チロシナーゼ活性促進作用による白髪改善効果(特許文献4)、血行促進作用(特許文献5)などが知られている。しかしながら、サンショウの幹細胞の増殖促進効果や未分化状態維持効果については、これまで何ら知られていない。 Japanese pepper (scientific name: Zanthoxylum piperitum) is a deciduous shrub belonging to the genus Zanthoxylum of the Rutaceae family, and its mature pericarp and immature fruit are used as a spice. In addition, the herbal medicine sansho (sansho) is a mature pericarp with as few seeds removed as possible. It is used in Chinese herbal medicine to improve stomach pain and bloating due to gastrointestinal function and enhance gastrointestinal function. So far, Japanese pepper has been known to have an effect of improving gray hair by promoting tyrosinase activity (Patent Document 4), promoting blood circulation (Patent Document 5), and the like. However, nothing has been known about the proliferation-promoting effect of Japanese pepper and the effect of maintaining an undifferentiated state of stem cells.
本発明は、上述した実情に鑑み、幹細胞を、未分化状態を維持させたまま、効率良く増殖させることができる新たな物質を見出し、幹細胞の未分化状態維持剤又は増殖促進剤として提供することを課題とする。 In view of the circumstances described above, the present invention seeks to find a new substance capable of efficiently proliferating stem cells while maintaining their undifferentiated state, and to provide the substance as an undifferentiated state-maintaining agent or proliferation-promoting agent for stem cells. is the subject.
本発明者らは、上記課題を解決するため鋭意研究を行った結果、サンショウの抽出物が、これまで知られていなかった幹細胞に対する優れた未分化状態維持効果及び増殖促進効果を有することを見出し、本発明を完成するに至った。 The inventors of the present invention conducted intensive research to solve the above problems, and as a result, found that the extract of Japanese pepper has an excellent undifferentiated state-maintaining effect and proliferation-promoting effect on stem cells, which was hitherto unknown. The discovery led to the completion of the present invention.
すなわち、本発明は、以下を包含する。
(1)サンショウの抽出物を有効成分として含有する幹細胞の未分化状態維持剤。
(2)サンショウの抽出物を有効成分として含有する幹細胞の増殖促進剤。
(3)前記幹細胞が毛包幹細胞である、(1)又は(2)に記載の剤。
(4)前記サンショウがブドウサンショウである、(1)~(3)のいずれかに記載の剤。
(5)サンショウの抽出物を含有する培地で培養する工程を含む、幹細胞の製造方法。
(6)幹細胞を、サンショウの抽出物を含有する培地で培養する工程を含む、幹細胞の未分化状態維持方法。
(7)幹細胞を、サンショウの抽出物を含有する培地で培養する工程を含む、幹細胞の増殖促進方法。
(8)前記幹細胞が毛包幹細胞である、(5)~(7)のいずれかに記載の方法。
(9)前記サンショウがブドウサンショウである、(5)~(8)のいずれかに記載の方法。
That is, the present invention includes the following.
(1) An agent for maintaining an undifferentiated state of stem cells containing an extract of Japanese pepper as an active ingredient.
(2) A proliferating agent for stem cells containing an extract of Japanese pepper as an active ingredient.
(3) The agent according to (1) or (2), wherein the stem cells are hair follicle stem cells.
(4) The agent according to any one of (1) to (3), wherein the Japanese pepper is grape Japanese pepper.
(5) A method for producing stem cells, which comprises the step of culturing in a medium containing an extract of Japanese pepper.
(6) A method for maintaining an undifferentiated state of stem cells, which comprises the step of culturing stem cells in a medium containing an extract of Japanese pepper.
(7) A method for promoting growth of stem cells, comprising the step of culturing stem cells in a medium containing an extract of Japanese pepper.
(8) The method according to any one of (5) to (7), wherein the stem cells are hair follicle stem cells.
(9) The method according to any one of (5) to (8), wherein the Japanese pepper is grape Japanese pepper.
本発明によれば、幹細胞を、未分化状態を維持したまま、効率的に増殖させることができる。従って、本発明は、再生医療や再生美容の分野において大きく貢献できるものである。 According to the present invention, stem cells can be efficiently proliferated while maintaining an undifferentiated state. Therefore, the present invention can greatly contribute to the fields of regenerative medicine and regenerative beauty.
以下、本発明を詳細に説明する。
発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、サンショウの抽出物を有効成分として含有する。
The present invention will be described in detail below.
An agent for maintaining an undifferentiated state or promoting proliferation of stem cells according to the present invention contains an extract of Japanese pepper as an active ingredient.
本発明に用いるサンショウ(山椒、学名:Zanthoxylum piperitum)は、ミカン科サンショウ属の落葉低木で、日本にも多く自生している。また、生薬の「サンショウ」(和名:山椒)の基原植物でもある。本発明において用いることのできるサンショウとしては、ミカン科サンショウ属のブドウザンショウ(学名:Zanthoxylum piperitum(L.)DC. f. inerme Makino)、アサクラザンショウ(Zanthoxylum piperitum(L.)DC forma inerme (Makino) Makino)、イヌザンショウ(Zanthoxylum schinifolium)、ヤマアサクラザンショウ(Zanthoxylum piperitum(L.)DC forma brevispinosum Makino)などが挙げられ、なかでもブドウザンショウが好ましい。 Japanese pepper (scientific name: Zanthoxylum piperitum) used in the present invention is a deciduous shrub belonging to the genus Zanthoxylum of the Rutaceae family, and grows naturally in Japan. It is also the original plant of the herbal medicine sansho (Japanese name: sansho). Examples of the Japanese pepper that can be used in the present invention include grape Japanese pepper belonging to the genus Zanthoxylum of the Rutaceae family (scientific name: Zanthoxylum piperitum (L.) DC f. inerme Makino), Zanthoxylum piperitum (L.) DC forma inerme (Makino) Makino), Zanthoxylum schinifolium, and Zanthoxylum piperitum (L.) DC forma brevispinosum Makino, among which Grape Zanthoxylum is preferred.
本発明においてサンショウの抽出物とは、サンショウの花、果実、果皮、茎、葉、枝、根、種子等の植物体の一部又は植物体全体、あるいはそれらの混合物の抽出物をいうが、本発明において抽出原料として使用する部位は、果皮や種子が好ましい。果皮(粉山椒)は、薬味として市販されているものを用いることができる。 In the present invention, the extract of Japanese pepper refers to an extract of a part or the whole plant such as flowers, fruits, pericarp, stems, leaves, branches, roots and seeds of Japanese pepper, or a mixture thereof. However, the part used as the raw material for extraction in the present invention is preferably the pericarp or the seed. Peel (powder Japanese pepper) can be used as a condiment.
サンショウから抽出物を得るための抽出方法は特に限定されず、例えば、加熱抽出方法であっても良いし、常温や冷温抽出方法であっても良い。抽出に使用する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1-プロパノール、2-プロパノール、1-ブタノール、2-ブタノール等)、液状多価アルコール類(1,3-ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)等が挙げられる。これらの溶媒のなかでも、水、低級アルコール及び液状多価アルコールが好ましく、水、エタノールがより好ましい。これらの溶媒は1種でも2種以上を混合して用いても良く、例えば30~70v/v%のエタノール水溶液を使用することもできる。また、上記抽出溶媒に酸やアルカリを添加して、pH調整した溶媒を使用することもできる。 The extraction method for obtaining an extract from Japanese pepper is not particularly limited, and may be, for example, a heat extraction method, a normal temperature extraction method, or a cold temperature extraction method. Solvents used for extraction include, for example, water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol , propylene glycol, glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran , propyl ether, etc.). Among these solvents, water, lower alcohols and liquid polyhydric alcohols are preferred, and water and ethanol are more preferred. These solvents may be used singly or in combination of two or more. For example, 30 to 70 v/v % ethanol aqueous solution may be used. Also, a solvent whose pH is adjusted by adding an acid or an alkali to the extraction solvent can be used.
溶媒の使用量については、特に限定はなく、例えば上記サンショウの果皮(乾燥重量)に対し、10倍以上、好ましくは20倍以上であればよいが、抽出後に濃縮を行なったり、単離したりする場合の操作の便宜上100倍以下であることが好ましい。また、抽出温度や時間は、用いる溶媒の種類によるが、例えば、10~100℃、好ましくは30~90℃で、30分~24時間、好ましくは1~10時間を例示することができる。より具体的には、サンショウの果皮に水を加え、95~100℃における熱水抽出を行うことで、サンショウの抽出物を得ることができる。あるいは、サンショウの果皮に低級アルコール(例えば、エタノール等)又は液状多価アルコール(例えば、プロピレングリコール、1,3-ブチレングリコール等)を添加し、常温(例えば5~35℃)で抽出を行うことで、サンショウの抽出物を得ることができる。 The amount of the solvent to be used is not particularly limited, and may be, for example, 10 times or more, preferably 20 times or more, relative to the pericarp (dry weight) of the Japanese pepper. For convenience of operation, it is preferably 100 times or less. The extraction temperature and time depend on the type of solvent used, but can be exemplified, for example, at 10 to 100° C., preferably 30 to 90° C., for 30 minutes to 24 hours, preferably 1 to 10 hours. More specifically, an extract of Japanese pepper can be obtained by adding water to the pericarp of Japanese pepper and performing hot water extraction at 95 to 100°C. Alternatively, a lower alcohol (e.g., ethanol, etc.) or a liquid polyhydric alcohol (e.g., propylene glycol, 1,3-butylene glycol, etc.) is added to the pericarp of Japanese pepper, and extraction is performed at room temperature (e.g., 5 to 35 ° C.). Thus, an extract of Japanese pepper can be obtained.
抽出物は、抽出した溶液のまま用いてもよいが、必要に応じて、その効果に影響のない範囲で、濃縮(有機溶媒、減圧濃縮、膜濃縮などによる濃縮)、希釈、濾過、活性炭等による脱色、脱臭、エタノール沈殿等の処理を行ってから用いてもよい。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いてもよい。 The extract may be used as an extracted solution, but if necessary, concentration (concentration by organic solvent, vacuum concentration, membrane concentration, etc.), dilution, filtration, activated carbon, etc., within a range that does not affect the effect. It may be used after being subjected to treatments such as decolorization, deodorization, and ethanol precipitation. Furthermore, the extracted solution may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.
このようにして得られたサンショウの抽出物は、生体レベルで又は培養レベルで未分化状態を維持させつつ幹細胞を効率的に増殖させる作用を有するので、幹細胞の未分化状態維持剤又は増殖促進剤として使用できる。さらに、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、幹細胞を、未分化状態を維持しつつ効率的に増殖させるための幹細胞培養用培地添加剤、研究用試薬としても使用することができる。 The extract of Japanese pepper obtained in this way has the effect of efficiently proliferating stem cells while maintaining an undifferentiated state at the biological level or at the culture level. Can be used as an agent. Furthermore, the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention is also used as a medium additive for stem cell culture and a research reagent for efficiently proliferating stem cells while maintaining an undifferentiated state. be able to.
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を、ヒトを含めた哺乳動物の幹細胞に適用することで、幹細胞の未分化状態を維持し、また幹細胞の増殖を促進することができる。本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を適用する幹細胞としては、本発明の目的に沿うものであれば特に限定されず、例えば胚性の幹細胞(ES細胞);骨髄、血液、皮膚(表皮、真皮、皮下組織)、脂肪、毛包、脳、神経、肝臓、膵臓、腎臓、筋肉やその他の組織に存在する体性の幹細胞;遺伝子導入等により人工的に作製された幹細胞(人工多能性幹細胞:iPS細胞)が挙げられる。本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、好ましくは、毛包幹細胞に対してより効果を発揮し、毛包内バルジ領域の毛包幹細胞の未分化状態を維持し、分化を抑制しながら、増殖を促進させることができる。ES細胞としては、例えば、着床以前の初期胚を培養することによって樹立されたES細胞、体細胞の核を核移植することによって作製された初期胚を培養することによって樹立されたES細胞、及びそれらのES細胞の染色体上の遺伝子を遺伝子工学の手法を用いて改変したES細胞が挙げられる。このようなES細胞は、例えば、自体公知の方法によって作製することができるが、所定の機関より入手でき、さらには市販品を購入することもできる。また、これらの幹細胞は、初代培養細胞、継代培養細胞又は凍結細胞のいずれであってもよい。 By applying the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention to stem cells of mammals including humans, the undifferentiated state of stem cells can be maintained and proliferation of stem cells can be promoted. . The stem cells to which the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention is applied are not particularly limited as long as they meet the purpose of the present invention. For example, embryonic stem cells (ES cells); , skin (epidermis, dermis, subcutaneous tissue), fat, hair follicles, brain, nerve, liver, pancreas, kidney, muscle, and other tissues; stem cells artificially produced by gene transfer, etc. (induced pluripotent stem cells: iPS cells). The agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention preferably exerts a greater effect on hair follicle stem cells, maintains the undifferentiated state of the hair follicle stem cells in the bulge region of the hair follicle, and differentiates them. can be promoted while suppressing ES cells include, for example, ES cells established by culturing pre-implantation early embryos, ES cells established by culturing early embryos produced by nuclear transfer of somatic cell nuclei, and ES cells in which the genes on the chromosome of these ES cells have been modified using genetic engineering techniques. Such ES cells can be produced, for example, by a method known per se, and can be obtained from predetermined institutions or purchased commercially. Moreover, these stem cells may be primary cultured cells, subcultured cells or frozen cells.
さらに、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、幹細胞の分化の方向性及び分化の過程等について同等の特性を持っていれば、全ての哺乳動物由来の幹細胞に応用が可能である。例えば、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、ヒト、サル、マウス、ラット、モルモット、ウサギ、ネコ、イヌ、ウマ、ウシ、ヒツジ、ヤギ、ブタ等の哺乳動物の幹細胞に対して効果を発揮することができる。 Furthermore, the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention can be applied to stem cells derived from all mammals, as long as they have the same characteristics regarding the direction of differentiation and the process of differentiation of stem cells. It is possible. For example, the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention can be stem cells from mammals such as humans, monkeys, mice, rats, guinea pigs, rabbits, cats, dogs, horses, cows, sheep, goats, and pigs. can be effective against
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤の幹細胞への適用は、生体外であっても生体内であってもよく、いずれの場合もその作用を発揮できる。従って、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、その有効量を添加した幹細胞培養用培地にて幹細胞を培養することによって、あるいは、ヒトを含む哺乳動物に投与することによって、幹細胞の未分化状態を維持し、増殖を促進することができる。 The agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention may be applied to stem cells either in vitro or in vivo, and the effect can be exhibited in either case. Therefore, the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention can be obtained by culturing stem cells in a stem cell culture medium containing an effective amount thereof, or by administering it to mammals including humans. , can maintain the undifferentiated state of stem cells and promote proliferation.
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、有効成分であるサンショウの抽出物が優れた幹細胞の未分化状態維持作用及び増殖促進作用を有するので、皮膚、骨芽、軟骨、筋肉、神経、脂肪、肝臓などの生体内の組織又は臓器の幹細胞に作用して当該組織又は臓器の障害又は損傷を治療、改善、及び予防するのに有効である。また、幹細胞は、加齢などに伴い減少又は機能低下することから、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、上記生体内の組織又は臓器の幹細胞の減少や機能低下に関連する疾患を治療、改善、及び予防するのに有効である。ここで、組織又は臓器の障害又は損傷、幹細胞の減少や機能低下に関連する疾患としては、例えば、皮膚関連では、シワ、タルミ、シミ、くすみ、肌荒れ、皮膚の肥厚、毛穴のひらき、ニキビ痕、創傷、瘢痕、ケロイドなどが挙げられ、薄毛や脱毛などの頭皮や毛髪の損傷も含まれる。また、骨関連では、骨粗しょう症、骨折(脊椎圧迫骨折、大腿骨頚部骨折等)など、軟骨疾患では、変形性関節症、関節リウマチ、椎間板ヘルニアなど、神経関連では、脊髄損傷、顔面神経麻痺、アルツハイマー病、筋萎縮性側索硬化症、パーキンソン病、加齢に伴う記憶低下など、血液関連では、再生不良性貧血、白血病など、心血管関連では心筋梗塞、閉塞性動脈硬化症など、歯科関連では歯周病、歯槽膿漏による歯槽骨損傷など、眼科関連では、網膜色素変性症、加齢黄斑変性症、緑内障など、肝臓・膵臓関連では肝炎、肝硬変、糖尿病などが挙げられるが、これらに限定されない。 The agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention is suitable for use in skin, osteoblasts, cartilage, since the extract of Japanese pepper, which is an active ingredient, has an excellent effect of maintaining an undifferentiated state and promoting proliferation of stem cells. , muscles, nerves, fat, liver, etc., and is effective in treating, ameliorating, and preventing injury or damage to tissues or organs in vivo. In addition, since stem cells decrease or their function deteriorates with aging, the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention is effective against the decrease or function deterioration of stem cells in the tissue or organ in the living body. Effective in treating, ameliorating and preventing associated diseases. Here, diseases related to tissue or organ damage or damage, reduction or functional decline of stem cells include, for example, skin-related wrinkles, sagging, spots, dullness, rough skin, thickened skin, open pores, and acne scars. , wounds, scars, keloids, etc., including scalp and hair damage such as thinning hair and hair loss. In addition, bone-related diseases such as osteoporosis and fractures (vertebral compression fractures, femoral neck fractures, etc.), cartilage-related diseases such as osteoarthritis, rheumatoid arthritis, and intervertebral disc herniation, and nerve-related diseases such as spinal cord injury and facial paralysis. , Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, age-related memory loss, etc. Blood-related diseases such as aplastic anemia, leukemia, etc. Cardiovascular-related diseases such as myocardial infarction, arteriosclerosis obliterans, etc. Dentistry Related diseases include periodontal disease and alveolar bone damage due to alveolar pyorrhea; ophthalmic diseases such as retinitis pigmentosa, age-related macular degeneration, and glaucoma; liver and pancreatic diseases such as hepatitis, cirrhosis, and diabetes. is not limited to
また、サンショウの抽出物は、毛包幹細胞の増殖促進作用及び未分化状態維持作用を有する。すなわち、サンショウの抽出物は、毛包内バルジ領域の毛包幹細胞の分化抑制により、毛髪の元になる毛包幹細胞の減少又は枯渇を阻止できるとともに、毛包幹細胞の増殖を促進することができるので、脱毛症の予防及び/又は改善剤の有効成分とすることができる。本発明において、「脱毛症の予防及び/又は改善」には、脱毛や薄毛の発生の阻止、脱毛や薄毛の程度(本数や範囲)の改善、脱毛や薄毛の進行速度の低下、脱毛や薄毛に伴う毛髪の光沢や弾性の減少の抑制などが含まれる。また、脱毛症の予防及び/又は改善効果は、頭髪に直接な作用機序を示す場合と頭部における経皮的な作用機序を示す場合の両方を含む。本発明において、脱毛症とは、例えば、加齢、疾患、紫外線や過労などの種々のストレスなどにより、毛髪の一部又は全部が抜けて、頭皮の一部又は全体が透けて見える症状をいう。脱毛症には、例えば、男性型脱毛症(AGA)、びまん性脱毛症(FAGA)、円形脱毛症、老人性脱毛症、脂漏性脱毛症、粃糠性脱毛症、産後(分娩後)脱毛症、機械性(圧迫性若しくは牽引性)脱毛症、先天性脱毛症、火傷又は外傷後の脱毛症、抗がん剤による薬剤性脱毛症、瘢痕性脱毛症(毛孔性扁平苔癬、紅斑性狼瘡、禿髪性毛包炎、頭部乳頭状皮膚炎等)、トリコチロマニア(抜毛症)などが含まれるが、これらに限定はされない。 In addition, the extract of Japanese pepper has the effect of promoting proliferation of hair follicle stem cells and the effect of maintaining an undifferentiated state. That is, the Japanese pepper extract can inhibit the differentiation or depletion of hair follicle stem cells in the bulge region of the hair follicle, thereby preventing the reduction or depletion of hair follicle stem cells and promoting the proliferation of hair follicle stem cells. Therefore, it can be used as an active ingredient of an agent for preventing and/or improving alopecia. In the present invention, "prevention and/or amelioration of alopecia" includes prevention of occurrence of hair loss or thinning hair, improvement of the degree (number or range) of hair loss or thinning hair, reduction in progress speed of hair loss or thinning hair, and reduction of hair loss or thinning hair. It includes the suppression of the decrease in luster and elasticity of hair associated with hair loss. In addition, the effect of preventing and/or improving alopecia includes both a direct action mechanism on the hair and a percutaneous action mechanism on the head. In the present invention, alopecia refers to a symptom in which part or all of the hair falls out due to aging, disease, various stresses such as ultraviolet rays and overwork, and part or all of the scalp becomes transparent. . Alopecia includes, for example, male pattern baldness (AGA), diffuse alopecia (FAGA), alopecia areata, senile alopecia, seborrheic alopecia, alopecia pityriasis, postpartum (postpartum) hair loss. disease, mechanical (pressure or traction) alopecia, congenital alopecia, alopecia after burns or trauma, drug-induced alopecia caused by anticancer drugs, scarring alopecia (lichen planus pilaris, erythematous lupus, folliculitis bald, papillary dermatitis of the head, etc.), trichotillomania (trichotillomania), etc., but not limited to these.
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤におけるサンショウの抽出物の含有量は、特に限定されないが、抽出物の性状(抽出液、濃縮物、又は乾燥物)により、例えば、0.00001~100重量%の範囲で適宜設定でき、0.0001~10重量%が好ましく、0.001~1重量%であることがより好ましい。 The content of the extract of Japanese pepper in the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention is not particularly limited, but depending on the properties of the extract (extract, concentrate, or dried product), for example, It can be appropriately set in the range of 0.00001 to 100% by weight, preferably 0.0001 to 10% by weight, more preferably 0.001 to 1% by weight.
本発明はまた、幹細胞を、サンショウの抽出物を含有する培地で培養することで、幹細胞の未分化状態を維持させたまま、幹細胞増殖を促進する方法に関する。換言すれば、本発明に係る方法は、幹細胞を、サンショウの抽出物を含有する培地で培養する工程を含む、幹細胞の製造方法、幹細胞の未分化状態維持方法、又は幹細胞の増殖促進方法ということができる。 The present invention also relates to a method for promoting stem cell proliferation while maintaining an undifferentiated state of stem cells by culturing stem cells in a medium containing an extract of Japanese pepper. In other words, the method according to the present invention is a method for producing stem cells, a method for maintaining an undifferentiated state of stem cells, or a method for promoting proliferation of stem cells, which comprises a step of culturing stem cells in a medium containing an extract of Japanese pepper. be able to.
本発明に係る方法において、幹細胞の培養には、幹細胞の未分化状態維持及び増殖のために一般的に使用されている培地を用いればよい。例えば、幹細胞の生存及び増殖に必要な成分(無機塩、炭水化物、ホルモン、必須アミノ酸、非必須アミノ酸、ビタミン、脂肪酸)を含む基本培地、具体的には、Dulbecco's Modified Eagle Medium(D-MEM)、Minimum Essential Medium(MEM)、RPMI1640、Basal Medium Eagle(BME)、Ham's F12、Ham's F12K(Kaighn's modified of Ham’s F12)、Dulbecco's Modified Eagle Medium:Nutrient Mixture F-12(D-MEM/F-12)、Glasgow inimum Essential Medium(Glasgow MEM)、ハンクス液(Hank's balanced salt solution)、MCDB153培地等が挙げられる。また、培地に、増殖因子[上皮細胞増殖因子(EGF)、コレラトキシン、塩基性線維芽細胞増殖因子(bFGF)、白血球遊走阻止因子(LIF)、Stem Cell Factor(SCF)等]、ホルモン(インスリン、ヒドロコルチゾン等)を添加することが好ましい。さらに、必要に応じて、培地は、腫瘍壊死因子(TNF)、ビタミン類、インターロイキン類、トランスフェリン、ヘパリン、ヘパラン硫酸、コラーゲン、フィブロネクチン、プロゲステロン、セレナイト、B27-サプリメント、N2-サプリメント、ITS-サプリメント、抗生物質等を含有してもよい。 In the method according to the present invention, stem cells may be cultured using media that are commonly used for maintaining and proliferating stem cells in an undifferentiated state. For example, a basal medium containing components (inorganic salts, carbohydrates, hormones, essential amino acids, non-essential amino acids, vitamins, fatty acids) necessary for the survival and proliferation of stem cells, specifically Dulbecco's Modified Eagle Medium (D-MEM), Minimum Essential Medium (MEM), RPMI1640, Basal Medium Eagle (BME), Ham's F12, Ham's F12K (Kaighn's modified of Ham's F12), Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (D-MEM/F-12), Glasgow inimum Essential Medium (Glasgow MEM), Hank's balanced salt solution, MCDB153 medium and the like. In addition, the medium contains growth factors [epidermal growth factor (EGF), cholera toxin, basic fibroblast growth factor (bFGF), leukocyte migration inhibitory factor (LIF), stem cell factor (SCF), etc.], hormones (insulin , hydrocortisone, etc.) are preferably added. In addition, if necessary, the medium contains tumor necrosis factor (TNF), vitamins, interleukins, transferrin, heparin, heparan sulfate, collagen, fibronectin, progesterone, selenite, B27-supplement, N2-supplement, ITS-supplement , antibiotics and the like.
また、上記の成分以外には、0.1~20%(v/v)の含有率でウシ脳下垂体抽出物(BPE)、血清又は血清代替物が培地に含まれることが好ましい。血清又は血清代替物は、公知のものであればいずれのものも用いることができる。例えば、血清としては、ウシ胎児血清(FBS、FCS)などが挙げられ、血清代替物としては、KSRなどが挙げられる。しかしながら、血清はロットの違いにより成分が異なり、その効果にバラツキがあるため、ロットチェックを行った後に使用することが好ましい。 In addition to the above components, the medium preferably contains bovine pituitary extract (BPE), serum or serum substitute at a content of 0.1 to 20% (v/v). Any known serum or serum substitute can be used. For example, serum includes fetal bovine serum (FBS, FCS) and the like, and serum substitutes include KSR and the like. However, since the components of serum differ depending on the lot, and the effect varies, it is preferable to use serum after lot check.
市販品の培地としては、インビトロジェン製の間葉系幹細胞基礎培地や、三光純薬製の間葉系幹細胞基礎培地、TOYOBO社製のMF培地、Sigma社製のハンクス液(Hank’s balanced salt solution)等を用いることができる。また、幹細胞が毛包幹細胞である場合は、上皮系細胞の培養に必要な成分(例えば、インスリン、ヒドロコルチゾン、上皮細胞増殖因子等)を含む市販の上皮系細胞用培地を用いればよく、例えば、Keratinocyte-SFM培地(Thermo Fisher Scientific社製)、Humedia-KG2培地(KURABO社)、CnT-PR培地(CellnTec社)、MCDB153培地(Sigma社製)、正常ヒトケラチノサイト用無血清培地(DSファーマバイオメディカル社製)等が挙げられる。 Commercially available media include Invitrogen's mesenchymal stem cell basal medium, Sanko Junyaku's mesenchymal stem cell basal medium, TOYOBO's MF medium, Sigma's Hank's balanced salt solution, etc. can be used. In addition, when the stem cells are hair follicle stem cells, commercially available epithelial cell culture media containing components necessary for culturing epithelial cells (e.g., insulin, hydrocortisone, epidermal cell growth factor, etc.) may be used. Keratinocyte-SFM medium (Thermo Fisher Scientific), Humedia-KG2 medium (KURABO), CnT-PR medium (CellnTec), MCDB153 medium (Sigma), serum-free medium for normal human keratinocytes (DS Pharma Biomedical company) and the like.
幹細胞の培養に用いる培養器は、幹細胞の培養が可能なものであれば特に限定されないが、例えば、フラスコ、シャーレ、ディッシュ、プレート、チャンバースライド、チューブ、トレイ、培養バッグ、ローラーボトルなどが挙げられる。 The incubator used for culturing stem cells is not particularly limited as long as it is capable of culturing stem cells. .
培養器は、細胞非接着性であっても接着性であってもよく、目的に応じて適宜選択される。細胞接着性の培養器は、細胞との接着性を向上させる目的で、細胞外マトリックス等による細胞支持用基質などで処理したものを用いてもよい。細胞支持用基質としては、例えば、コラーゲン、ゼラチン、ポリ-L-リジン、ポリ-D-リジン、ラミニン、フィブロネクチンなどが挙げられる。 The incubator may be cell non-adhesive or adhesive, and is appropriately selected depending on the purpose. Cell-adhesive incubators may be treated with cell-supporting substrates such as extracellular matrices for the purpose of improving adhesion to cells. Cell-supporting matrices include, for example, collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin and the like.
幹細胞培養に使用される培地に対するサンショウの抽出物の添加濃度は、上述の本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤におけるサンショウの抽出物の含有量に準じて適宜決定することができるが、サンショウの乾燥物に換算して、例えば10~10000μg/mL、好ましくは100~5000μg/mLの濃度が挙げられる。また、幹細胞の培養期間中、これらの抽出物を定期的に培地に添加してもよい。 The concentration of the Japanese pepper extract added to the medium used for stem cell culture is appropriately determined according to the content of the Japanese pepper extract in the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention. However, the concentration is, for example, 10 to 10,000 μg/mL, preferably 100 to 5,000 μg/mL in terms of dried Japanese pepper. Also, these extracts may be periodically added to the medium during the culture period of the stem cells.
幹細胞の培養条件は、幹細胞の培養に用いられる通常の条件に従えばよく、特別な制御は必要ではない。例えば、培養温度は、特に限定されるものではないが約30~40℃、好ましくは36~37℃である。CO2ガス濃度は、例えば約1~10%、好ましくは約2~5%である。なお、培地の交換は2~3日に1回行うことが好ましく、毎日行うことがより好ましい。前記培養条件は、幹細胞が生存及び増殖可能な範囲で適宜変動させて設定することもできる。 The conditions for culturing stem cells may follow the usual conditions used for culturing stem cells, and no special control is required. For example, the culture temperature is not particularly limited, but is about 30-40°C, preferably 36-37°C. The CO 2 gas concentration is, for example, about 1-10%, preferably about 2-5%. The culture medium is preferably exchanged once every 2 to 3 days, more preferably every day. The culture conditions can also be set by appropriately varying them within a range in which stem cells can survive and proliferate.
幹細胞の未分化状態維持は、例えば、本発明に係る幹細胞の未分化状態維持剤の非存在下で培養した幹細胞と比較して、本発明に係る幹細胞の未分化状態維持剤の存在下で培養した該幹細胞において幹細胞未分化マーカー遺伝子の発現レベルがmRNAレベル又はタンパク質レベルで培養開始時の発現レベルと同程度のレベルに有意に維持されているか否かで評価することができる。幹細胞未分化マーカー遺伝子としては、例えばNanog遺伝子(Cell Res.2007 Jan;17(1):42-9.Review.Nanog and transcriptional networks in embryonic stem cell pluripotency.Pan G,Thomson JA.)等が挙げられる。また、毛包幹細胞未分化マーカー遺伝子としては、例えばKRT15(Keratin, type I cytoskeletal 15)等が挙げられる。 For maintaining an undifferentiated state of stem cells, for example, compared with stem cells cultured in the absence of the agent for maintaining an undifferentiated state of stem cells according to the present invention, the stem cells are cultured in the presence of the agent for maintaining an undifferentiated state of stem cells according to the present invention. Evaluation can be made by determining whether the expression level of the undifferentiated stem cell marker gene is significantly maintained at the mRNA level or protein level in the stem cells that have been cultured, at a level comparable to that at the start of culture. Examples of undifferentiated stem cell marker genes include Nanog gene (Cell Res. 2007 Jan; 17(1): 42-9. Review. Nanog and transcriptional networks in embryonic stem cell pluripotency. Pan G, Thomson JA.). . Examples of hair follicle stem cell undifferentiated marker genes include KRT15 (Keratin, type I cytoskeletal 15).
幹細胞未分化マーカー遺伝子発現レベルの測定方法としては、mRNAレベルでは、例えば幹細胞未分化マーカー遺伝子に特異的なプライマーやプローブを用いたRT-PCR、定量PCRやノーザンブロッティング等の方法が挙げられ、また、タンパク質レベルでは、例えば幹細胞未分化マーカー遺伝子によりコードされるタンパク質に特異的な抗体を用いたELISA、フローサイトメトリー、ウエスタンブロッティング等の免疫学的方法が挙げられる。 Methods for measuring the stem cell undifferentiated marker gene expression level include, at the mRNA level, methods such as RT-PCR, quantitative PCR, and Northern blotting using primers and probes specific to the stem cell undifferentiated marker gene. At the protein level, immunological methods such as ELISA, flow cytometry, Western blotting, etc. using antibodies specific to proteins encoded by undifferentiated stem cell marker genes can be used.
発現レベルの測定の結果、培養開始時(100%未分化状態)の幹細胞における幹細胞未分化マーカー遺伝子の発現レベルと本発明の幹細胞の未分化状態維持剤の存在下で所定時間培養後の幹細胞における幹細胞未分化マーカー遺伝子の発現レベルとの相対比が、本発明の幹細胞の未分化状態維持剤の非存在下で培養した場合の同相対比(コントロール)よりも大きい場合に幹細胞の未分化状態を維持できたと判定することができる。 As a result of measuring the expression level, the expression level of the stem cell undifferentiated marker gene in the stem cells at the start of culture (100% undifferentiated state) and the stem cell after culturing for a predetermined time in the presence of the agent for maintaining the undifferentiated state of stem cells of the present invention When the relative ratio to the expression level of the undifferentiated stem cell marker gene is greater than the same relative ratio (control) when the stem cells are cultured in the absence of the agent for maintaining the undifferentiated state of the stem cells of the present invention, the undifferentiated state of stem cells is indicated. can be determined to be maintained.
また、幹細胞の増殖促進は、例えば、本発明に係る幹細胞の増殖促進剤の非存在下で培養した幹細胞と比較して、本発明に係る幹細胞の増殖促進剤の存在下で培養した該幹細胞の細胞数が有意に増加されているか否かで評価することができる。細胞数の測定は、例えば、MTT法やWST法などにより、市販の細胞数測定キットを用いて行うことができる。測定の結果、培養開始時の幹細胞の細胞数と本発明の幹細胞の増殖促進剤の存在下で所定時間培養後の幹細胞の細胞数との相対比が、本発明の幹細胞の増殖促進剤の非存在下で培養した場合の同相対比(コントロール)よりも大きい場合に幹細胞の増殖を促進できたと判定することができる。 In addition, stem cell proliferation promotion is, for example, compared to stem cells cultured in the absence of the stem cell proliferation-promoting agent of the present invention. It can be evaluated by whether or not the number of cells is significantly increased. The cell count can be measured, for example, by the MTT method, WST method, or the like, using a commercially available cell count measurement kit. As a result of the measurement, the relative ratio between the number of stem cells at the start of culture and the number of stem cells after culturing for a predetermined period of time in the presence of the agent for promoting proliferation of stem cells of the present invention was It can be determined that the proliferation of stem cells has been promoted when the ratio is greater than the same relative ratio (control) when cultured in the presence.
上記の本発明に係る方法により調製された幹細胞は移植材料(細胞移植剤)として用いることができ、従来の骨髄移植又は臍帯血移植と同一の方法で実施できる。 Stem cells prepared by the above method according to the present invention can be used as a transplant material (cell transplant agent), and can be performed in the same manner as conventional bone marrow transplantation or umbilical cord blood transplantation.
上記の本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤あるいは本発明に係る方法に準じて、サンショウの抽出物を、単独で、あるいは培地と別々に又は培地と混合し、幹細胞の未分化状態維持又は増殖促進のための試薬キットとして提供することもできる。当該キットは、必要に応じて取扱い説明書等を含むことができる。あるいは、サンショウの抽出物を培地と混合し、幹細胞の未分化状態維持又は増殖促進用培地として提供することもできる。 According to the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention or the method according to the present invention, the extract of Japanese pepper is used alone, separately from the medium, or mixed with the medium to produce stem cells. It can also be provided as a reagent kit for maintaining an undifferentiated state or promoting proliferation. The kit can contain an instruction manual and the like as necessary. Alternatively, a Japanese pepper extract can be mixed with a medium and provided as a medium for maintaining an undifferentiated state or promoting proliferation of stem cells.
本発明に係る上記の幹細胞の未分化状態維持剤又は増殖促進剤を生体内に投与する場合は、そのまま投与することも可能であるが、本発明の効果を損なわない範囲で適当な添加物とともに化粧品、医薬部外品、医薬品、飲食品等の各種組成物に配合して提供することができる。なお、本発明の医薬品には、動物に用いる薬剤、即ち獣医薬も包含されるものとする。 When the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention is administered in vivo, it may be administered as it is, but it may be administered together with an appropriate additive to the extent that the effects of the present invention are not impaired. It can be provided by blending in various compositions such as cosmetics, quasi-drugs, pharmaceuticals, and food and drink. The drug of the present invention also includes drugs used for animals, that is, veterinary drugs.
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を化粧品や医薬部外品に配合する場合は、その剤形は、水溶液系、可溶化系、乳化系、粉末系、粉末分散系、油液系、ゲル系、軟膏系、エアゾール系、水-油二層系、又は水-油-粉末三層系等のいずれでもよい。また、当該化粧品や医薬部外品は、幹細胞の未分化状態維持剤又は増殖促進剤とともに、皮膚外用組成物において通常使用されている各種成分、添加剤、基剤等をその種類に応じて選択し、適宜配合し、当分野で公知の手法に従って製造することができる。その形態は、液状、乳液状、クリーム状、ゲル状、ペースト状、スプレー状等のいずれであってもよい。皮膚外用組成物の配合成分としては、例えば、油脂類(オリーブ油、ヤシ油、月見草油、ホホバ油、ヒマシ油、硬化ヒマシ油等)、ロウ類(ラノリン、ミツロウ、カルナウバロウ等)、炭化水素類(流動パラフィン、スクワレン、スクワラン、ワセリン等)、脂肪酸類(ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘニン酸等)、高級アルコール類(ミリスチルアルコール、セタノール、セトステアリルアルコール、ステアリルアルコール、ベヘニルアルコール等)、エステル類(ミリスチン酸イソプロピル、パルミチン酸イソプロピル、オクタン酸セチル、トリオクタン酸グリセリン、ミリスチン酸オクチルドデシル、ステアリン酸オクチル、ステアリン酸ステアリル等)、有機酸類(クエン酸、乳酸、α-ヒドロキシ酢酸、ピロリドンカルボン酸等)、糖類(マルチトール、ソルビトール、キシロビオース、N-アセチル-D-グルコサミン等)、蛋白質及び蛋白質の加水分解物、アミノ酸類及びその塩、ビタミン類、植物・動物抽出成分、種々の界面活性剤、保湿剤、紫外線吸収剤、抗酸化剤、安定化剤、防腐剤、殺菌剤、香料等が挙げられる。 When the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention is incorporated in cosmetics or quasi-drugs, the dosage form may be an aqueous solution system, a solubilization system, an emulsification system, a powder system, a powder dispersion system, Any of an oil-based system, a gel system, an ointment system, an aerosol system, a water-oil two-layer system, or a water-oil-powder three-layer system may be used. In addition, for the cosmetics and quasi-drugs, various ingredients, additives, bases, etc. that are usually used in external skin compositions are selected according to the type, along with the agent for maintaining the undifferentiated state of stem cells or the agent for promoting proliferation. and can be appropriately blended and manufactured according to techniques known in the art. The form may be liquid, emulsion, cream, gel, paste, spray, or the like. Examples of components of the external composition for skin include oils and fats (olive oil, coconut oil, evening primrose oil, jojoba oil, castor oil, hydrogenated castor oil, etc.), waxes (lanolin, beeswax, carnauba wax, etc.), hydrocarbons ( Liquid paraffin, squalene, squalane, petrolatum, etc.), fatty acids (lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, etc.), higher alcohols (myristyl alcohol, cetanol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, etc.) , esters (isopropyl myristate, isopropyl palmitate, cetyl octanoate, glyceryl trioctanoate, octyldodecyl myristate, octyl stearate, stearyl stearate, etc.), organic acids (citric acid, lactic acid, α-hydroxyacetic acid, pyrrolidone carboxylic acid) acids, etc.), sugars (maltitol, sorbitol, xylobiose, N-acetyl-D-glucosamine, etc.), proteins and protein hydrolysates, amino acids and their salts, vitamins, plant/animal extracts, various surfactants agents, moisturizing agents, ultraviolet absorbers, antioxidants, stabilizers, preservatives, bactericides, fragrances and the like.
化粧品や医薬部外品の種類としては、例えば、化粧水、乳液、ジェル、美容液、一般クリーム、日焼け止めクリーム、パック、マスク、洗顔料、化粧石鹸、ファンデーション、おしろい、浴用剤、ボディローション、ボディシャンプー、ヘアシャンプー、ヘアコンディショナー、育毛剤等が挙げられる。 Types of cosmetics and quasi-drugs include lotions, milky lotions, gels, serums, general creams, sunscreen creams, packs, masks, facial cleansers, toilet soaps, foundations, powders, bath agents, body lotions, body shampoos, hair shampoos, hair conditioners, hair restorers, and the like.
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を医薬品に配合する場合は、薬理学的及び製剤学的に許容しうる添加物と混合し、患部に適用するのに適した製剤形態の各種製剤に製剤化することができる。薬理学的及び製剤学的に許容しうる添加物としては、その剤形、用途に応じて、適宜選択した製剤用基材や担体、賦形剤、希釈剤、結合剤、滑沢剤、コーティング剤、崩壊剤又は崩壊補助剤、安定化剤、保存剤、防腐剤、増量剤、分散剤、湿潤化剤、緩衝剤、溶解剤又は溶解補助剤、等張化剤、pH調節剤、噴射剤、着色剤、甘味剤、矯味剤、香料等を適宜添加し、公知の種々の方法にて経口又は非経口的に全身又は局所投与することができる各種製剤形態に調製すればよい。本発明の医薬品を上記の各形態で提供する場合、通常当業者に用いられる製法、たとえば日本薬局方の製剤総則[2]製剤各条に示された製法等により製造することができる。 When the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention is incorporated into a pharmaceutical, the dosage form is suitable for mixing with pharmacologically and pharmaceutically acceptable additives and applying to the affected area. It can be formulated into various formulations of Pharmacologically and pharmaceutically acceptable additives include formulation bases and carriers, excipients, diluents, binders, lubricants, and coatings that are appropriately selected according to the dosage form and application. agent, disintegrant or disintegration aid, stabilizer, preservative, preservative, bulking agent, dispersant, wetting agent, buffer, solubilizer or dissolution aid, tonicity agent, pH adjuster, propellant , colorants, sweeteners, corrigents, flavoring agents, etc., may be added as appropriate, and various formulations that can be administered systemically or locally via oral or parenteral administration may be prepared by various known methods. When the drug of the present invention is provided in each of the forms described above, it can be produced by a method commonly used by those skilled in the art, for example, the method shown in the Japanese Pharmacopoeia General Rules for Formulations [2] Each article for formulations.
本発明の医薬品の形態としては、特に制限されるものではないが、例えば錠剤、糖衣錠剤、カプセル剤、トローチ剤、顆粒剤、散剤、液剤、丸剤、乳剤、シロップ剤、懸濁剤、エリキシル剤などの経口剤、注射剤(例えば、皮下注射剤、静脈内注射剤、筋肉内注射剤、腹腔内注射剤)、点滴剤、座剤、軟膏剤、ローション剤、点眼剤、噴霧剤、経皮吸収剤、経粘膜吸収剤、貼付剤などの非経口剤などが挙げられる。また、使用する際に再溶解させる乾燥生成物にしてもよく、注射用製剤の場合は単位投与量アンプル又は多投与量容器の状態で提供される。 The form of the pharmaceutical of the present invention is not particularly limited, but examples include tablets, sugar-coated tablets, capsules, lozenges, granules, powders, liquids, pills, emulsions, syrups, suspensions, and elixirs. oral agents such as agents, injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), drips, suppositories, ointments, lotions, eye drops, sprays, oral Examples include parenteral agents such as skin absorbers, transmucosal absorbers, and patches. It may also be a dry product to be reconstituted for use, and in the case of an injectable formulation, provided in unit dose ampules or multi-dose containers.
本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤を、前記皮膚関連の損傷や疾患を治療、改善、及び予防するための医薬品として用いる場合に適した形態は外用製剤であり、例えば、軟膏剤、クリーム剤、ゲル剤、液剤、貼付剤(パップ剤、プラスター剤)、フォーム剤、スプレー剤、噴霧剤などが挙げられる。軟膏剤は、均質な半固形状の外用製剤をいい、油脂性軟膏、乳剤性軟膏、水溶性軟膏を含む。ゲル剤は、水不溶性成分の抱水化合物を水性液に懸濁した外用製剤をいう。液剤は、液状の外用製剤をいい、ローション剤、懸濁剤、乳剤、リニメント剤等を含む。 When the agent for maintaining an undifferentiated state of stem cells or the agent for promoting proliferation of stem cells according to the present invention is used as a pharmaceutical for treating, ameliorating, and preventing the aforementioned skin-related injuries and diseases, a suitable form is an external preparation, for example, Examples include ointments, creams, gels, liquids, patches (plasts, plasters), foams, sprays, sprays, and the like. An ointment refers to a homogeneous semi-solid preparation for external use, including oleaginous ointment, emulsion ointment, and water-soluble ointment. A gel is an external preparation in which a water-insoluble hydrate compound is suspended in an aqueous solution. Liquid preparations refer to liquid preparations for external use, including lotions, suspensions, emulsions, liniments and the like.
本発明の医薬品は、上記疾患の発症を抑制する予防薬として、及び/又は、正常な状態に改善する治療薬として機能する。本発明の医薬品の有効成分は、天然物由来であるため、非常に安全性が高く副作用がないため、前述の疾患の治療、改善、及び予防用医薬として用いる場合、ヒト、マウス、ラット、ウサギ、イヌ、ネコ等の哺乳動物に対して広い範囲の投与量で経口的に又は非経口的に投与することができる。 The medicament of the present invention functions as a prophylactic drug that suppresses the onset of the above diseases and/or as a therapeutic drug that improves normal conditions. Since the active ingredient of the pharmaceutical of the present invention is derived from natural products, it is extremely safe and has no side effects. It can be administered orally or parenterally to mammals such as , dogs and cats in a wide range of doses.
本発明の化粧品、医薬品、医薬部外品における幹細胞の未分化状態維持剤又は増殖促進剤の含有量は特に限定されないが、製剤(組成物)全重量に対して、サンショウの抽出物の乾燥物に換算して、0.001~30重量%が好ましく、0.01~10重量%がより好ましい。上記の量があくまで例示であって、組成物の種類や形態、一般的な使用量、効能・効果などを考慮して適宜設定・調整すればよい。また、製剤化における有効成分の添加法については、予め加えておいても、製造途中で添加してもよく、作業性を考えて適宜選択すればよい。 The content of the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells in the cosmetics, pharmaceuticals, and quasi-drugs of the present invention is not particularly limited. It is preferably 0.001 to 30% by weight, more preferably 0.01 to 10% by weight, in terms of a substance. The above amounts are only examples, and may be appropriately set and adjusted in consideration of the type and form of the composition, the general usage amount, efficacy and effects, and the like. In addition, the method of adding the active ingredient in formulation may be added in advance or may be added during the production, and may be appropriately selected in consideration of workability.
また、本発明に係る幹細胞の未分化状態維持剤又は増殖促進剤は、飲食品にも配合できる。また、本発明において、飲食品とは、一般的な飲食品のほか、医薬品以外で健康の維持や増進を目的として摂取できる食品、例えば、健康食品、機能性食品、保健機能食品、又は特別用途食品を含む意味で用いられる。健康食品には、栄養補助食品、健康補助食品、サプリメント等の名称で提供される食品を含む。保健機能食品は食品衛生法又は健康増進法により定義され、特定の保健の効果や栄養成分の機能、疾病リスクの低減などを表示できる、特定保健用食品及び栄養機能食品、ならびに科学的根拠に基づいた機能性について消費者庁長官に届け出た内容を表示できる機能性表示食品が含まれる。また特別用途食品には、特定の対象者や特定の疾患を有する患者に適する旨を表示する病者用食品、高齢者用食品、乳児用食品、妊産婦用食品等が含まれる。幹細胞が毛包幹細胞である場合は、本剤は、抜け毛や薄毛を予防又は改善するための健康食品に好適に用いることができる。ここで、飲食品に付される特定の保健の効果や栄養成分の機能等の表示は、製品の容器、包装、説明書、添付文書などの表示物、製品のチラシやパンフレット、新聞や雑誌等の製品の広告などにすることができる。 In addition, the agent for maintaining an undifferentiated state of stem cells or the agent for promoting growth of stem cells according to the present invention can also be added to food and drink. In addition, in the present invention, food and drink means general food and drink, as well as foods other than pharmaceuticals that can be ingested for the purpose of maintaining or improving health, such as health foods, functional foods, health functional foods, or special purpose foods. Used in the sense of including food. Health foods include foods provided under the names of nutritional supplements, health supplements, supplements, and the like. Foods with health claims are defined by the Food Sanitation Act or the Health Promotion Act. This includes foods with function claims that can display the content notified to the Commissioner of the Consumer Affairs Agency regarding the functionality of the food. Foods for special dietary uses include foods for the sick, foods for the elderly, foods for infants, foods for pregnant women, etc., which are labeled as suitable for specific subjects or patients with specific diseases. When the stem cells are hair follicle stem cells, the agent can be suitably used in health foods for preventing or improving hair loss and thinning hair. Here, indications such as specific health effects and functions of nutritional ingredients attached to foods and drinks are indicated on product containers, packaging, instructions, and attached documents, product flyers and pamphlets, newspapers and magazines, etc. can be advertisements for products, etc.
飲食品の形態は、食用に適した形態、例えば、固形状、液状、顆粒状、粒状、粉末状、カプセル状、クリーム状、ペースト状のいずれであってもよい。特に、上記の健康食品等の場合の形状としては、例えば、タブレット状、丸状、カプセル状、粉末状、顆粒状、細粒状、トローチ状、液状(シロップ状、乳状、懸濁状を含む)等が好ましい。 The form of food and drink may be any form suitable for eating, such as solid, liquid, granule, grain, powder, capsule, cream, or paste. In particular, the shape of the above-mentioned health food and the like is, for example, tablet, round, capsule, powder, granule, fine grain, troche, liquid (including syrup, milk, and suspension). etc. are preferred.
飲食品の種類としては、パン類、麺類、菓子類、乳製品、水産・畜産加工食品、油脂及び油脂加工食品、調味料、各種飲料(清涼飲料、炭酸飲料、美容ドリンク、栄養飲料、果実飲料、乳飲料など)及び該飲料の濃縮原液及び調整用粉末等が挙げられるが、これらに限定はされない。 Types of food and drink include bread, noodles, confectionery, dairy products, marine and livestock processed foods, oils and fats processed foods, seasonings, various beverages (soft drinks, carbonated drinks, beauty drinks, nutritional drinks, fruit drinks , dairy beverages, etc.), and concentrated stock solutions and powders for preparation of such beverages, but are not limited thereto.
本発明の飲食品は、その種類に応じて通常使用される添加物を適宜配合してもよい。添加物としては、食品衛生法上許容されうる添加物であればいずれも使用できるが、例えば、ブドウ糖、ショ糖、果糖、異性化液糖、アスパルテーム、ステビア等の甘味料;クエン酸、リンゴ酸、酒石酸等の酸味料;デキストリン、デンプン等の賦形剤;結合剤、希釈剤、香料、着色料、緩衝剤、増粘剤、ゲル化剤、安定剤、保存剤、乳化剤、分散剤、懸濁化剤、防腐剤などが挙げられる。 The food or drink of the present invention may contain additives that are commonly used depending on the type thereof. Any additive can be used as long as it is acceptable under the Food Sanitation Act. Examples include sweeteners such as glucose, sucrose, fructose, isomerized liquid sugar, aspartame, and stevia; citric acid and malic acid. , acidulants such as tartaric acid; excipients such as dextrin and starch; binders, diluents, flavoring agents, coloring agents, buffering agents, thickening agents, gelling agents, A turbidity agent, a preservative, etc. are mentioned.
本発明の飲食品が一般的な飲食品の場合は、その飲食品の通常の製造工程においてサンショウの抽出物を添加する工程を含めることによって製造することができる。また健康食品の場合は、前記の医薬品の製造方法に準じればよく、例えば、タブレット状のサプリメントでは、サンショウの抽出物に、賦形剤等の添加物を添加、混合し、打錠機等で圧力をかけて成形することにより製造することができる。また、必要に応じてその他の材料(例えば、ビタミンC、ビタミンB2、ビタミンB6等のビタミン類、カルシウムなどのミネラル類、食物繊維等)を添加することもできる。 When the food or drink of the present invention is a general food or drink, it can be produced by including a step of adding an extract of Japanese pepper in the normal manufacturing process of the food or drink. In the case of health foods, the manufacturing method for pharmaceuticals may be followed. For example, in the case of tablet supplements, additives such as excipients are added to the extract of Japanese pepper, mixed, and processed by a tableting machine. It can be manufactured by molding by applying pressure such as. In addition, other materials (for example, vitamins such as vitamin C, vitamin B 2 and vitamin B 6 , minerals such as calcium, dietary fiber, etc.) can be added as necessary.
本発明の飲食品におけるサンショウの抽出物の配合量は、幹細胞の未分化状態維持効果及び増殖促進効果を発揮できる量であればよいが、対象飲食品の一般的な摂取量、飲食品の形態、効能・効果、呈味性、嗜好性及びコストなどを考慮して適宜設定すればよい。 The amount of the Japanese pepper extract in the food and drink of the present invention may be any amount that can exhibit the effect of maintaining the undifferentiated state and the effect of promoting proliferation of stem cells. It may be appropriately set in consideration of form, efficacy/effect, taste, palatability, cost, and the like.
以下、実施例を用いて本発明をより詳細に説明するが、本発明の技術的範囲はこれら実施例に限定されるものではない。 EXAMPLES The present invention will be described in more detail below using examples, but the technical scope of the present invention is not limited to these examples.
[実施例1] サンショウの抽出物の製造例
サンショウの抽出物を以下のとおり製造した。
(製造例1)ブドウザンショウの果皮の50%エタノール抽出物の製造
ブドウザンショウ果皮の乾燥物10gを200mLの50%(v/v)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固してブドウザンショウ果皮の50%エタノール抽出物を1.0g得た。
[Example 1] Production example of extract of Japanese pepper An extract of Japanese pepper was produced as follows.
(Production Example 1) Production of 50% Ethanol Extract of Pericarp of Grape Zanthoxylum 10 g of dried grape zanthoxylum pericarp was immersed in 200 mL of a 50% (v/v) ethanol aqueous solution at room temperature for 4 days. The resulting extract was filtered and then concentrated to dryness using an evaporator to obtain 1.0 g of a 50% ethanol extract of the pericarp of grape zanthoxylum.
(製造例2)ブドウザンショウの果皮の熱水抽出物の製造
ブドウザンショウ果皮の乾燥物10gに200mLの水を加え、95~100℃で2時間抽出した。得られた抽出液を濾過し、そのろ液を濃縮し、凍結乾燥してブドウザンショウ果皮の熱水抽出物を2.3g得た。
(Production Example 2) Production of Hot Water Extract of Pericarp of Grape Zanthoxylum 200 mL of water was added to 10 g of dried grape zanthoxylum pericarp and extracted at 95 to 100° C. for 2 hours. The resulting extract was filtered, and the filtrate was concentrated and freeze-dried to obtain 2.3 g of a hot water extract of grape zanthoxylum pericarp.
(製造例3)ブドウザンショウの果皮のエタノール抽出物の製造
ブドウザンショウ果皮の乾燥物10gを200mLのエタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固してブドウザンショウ果皮のエタノール抽出物を0.5g得た。
(Production Example 3) Production of Ethanol Extract of Pericarp of Grape Zanthoxylum 10 g of dried grape zanthoxylum pericarp was immersed in 200 mL of an ethanol aqueous solution at room temperature for 4 days. The resulting extract was filtered and then concentrated to dryness using an evaporator to obtain 0.5 g of an ethanol extract of the pericarp of grape zanthoxylum.
(製造例4)ブドウザンショウの種子の50%エタノール抽出物の製造
ブドウザンショウ種子の乾燥物10gを200mLの50%(v/v)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固してブドウザンショウ種子の50%エタノール抽出物を1.0g得た。
(Production Example 4) Production of 50% Ethanol Extract of Grape Zanthoxylum Seeds 10 g of dried grape Zanthoxylum seed was immersed in 200 mL of a 50% (v/v) aqueous ethanol solution at room temperature for 4 days. The resulting extract was filtered and then concentrated to dryness using an evaporator to obtain 1.0 g of a 50% ethanol extract of grape zanthoxylum seeds.
(製造例5)アサクラザンショウの果皮の50%エタノール抽出物の製造
アサクラザンショウ果皮の乾燥物10gを200mLの50%(v/v)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固してアサクラザンショウ果皮の50%エタノール抽出物を1.0g得た。
(Production Example 5) Production of 50% Ethanol Extract of Pericarp of Zanthoxylum japonicum 10 g of dried pericarp of Zanthoxylum japonicum was immersed in 200 mL of a 50% (v/v) aqueous ethanol solution at room temperature for 4 days. The resulting extract was filtered and then concentrated to dryness using an evaporator to obtain 1.0 g of a 50% ethanol extract of the pericarp of Asakura Zanthoxylum.
(製造例6)アサクラザンショウの果皮の熱水抽出物の製造
アサクラザンショウ果皮の乾燥物10gに200mLの水を加え、95~100℃で2時間抽出した。得られた抽出液を濾過し、そのろ液を濃縮し、凍結乾燥してアサクラザンショウ果皮の熱水抽出物を2.3g得た。
(Production Example 6) Production of hot water extract of pericarp of Asakula Zanthoxylum 200 mL of water was added to 10 g of dried pericarp of Asakula Zangtho, and extracted at 95 to 100°C for 2 hours. The resulting extract was filtered, and the filtrate was concentrated and freeze-dried to obtain 2.3 g of a hot water extract of pericarp of Asakura Zanthoxylum.
(製造例7)アサクラザンショウの果皮のエタノール抽出物の製造
アサクラサンショウ果皮の乾燥物10gを200mLのエタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固してアサクラザンショウ果皮のエタノール抽出物を0.5g得た。
(Production Example 7) Production of Ethanol Extract of Pericarp of Asakura Zanthoxylum 10 g of dried pericarp of Asakura Zanthoxylum was immersed in 200 mL of an ethanol aqueous solution at room temperature for 4 days. The resulting extract was filtered and then concentrated to dryness using an evaporator to obtain 0.5 g of an ethanol extract of the pericarp of Asakura Zanthoxylum.
(製造例8)アサクラザンショウの種子の50%エタノール抽出物の製造
アサクラザンショウ種子の乾燥物10gを200mLの50%(v/v)エタノール水溶液に室温で4日間浸漬した。得られた抽出液を濾過した後エバポレーターで濃縮乾固してアサクラザンショウ種子の50%エタノール抽出物を1.0g得た。
(Production Example 8) Production of 50% Ethanol Extract of Seeds of Zanthoxylum japonicum 10 g of dried Zanthoxylum japonicum seeds were immersed in 200 mL of a 50% (v/v) aqueous ethanol solution at room temperature for 4 days. The resulting extract was filtered and then concentrated to dryness using an evaporator to obtain 1.0 g of a 50% ethanol extract of Asakurazansho seeds.
[実施例2]サンショウの抽出物の毛包幹細胞に対する増殖促進効果及び未分化状態維持効果
以下に、実施例1において製造したサンショウの抽出物を用いた、幹細胞に対する増殖促進効果及び未分化状態維持効果の実験例とその結果を示す。
[Example 2] Proliferation-promoting effect and undifferentiated state-maintaining effect of Japanese pepper extract on hair follicle stem cells The proliferation-promoting effect and undifferentiated state-maintaining effect on stem cells using the Japanese pepper extract produced in Example 1 will be described below. An experimental example of the state maintenance effect and its results are shown.
(実験例1)サンショウの抽出物の毛包幹細胞に対する増殖促進効果の評価
(1)ヒト毛包幹細胞の培養
ヒトの毛髪を毛抜きで採取し、メス等を用いて毛包組織のバルジ領域を含む組織を回収した。PBS(-)にて洗浄した後、トリプシン(BD Biosciences社製)処理を行った。その後、セルストレイナー(FALCON社製)を用いて、細胞を単離し、回収した。回収した細胞を培養プレートに播種し、KG2培地(KURABO社製)を用いてコンフルエントになるまで維持した。コンフルエントになった細胞を回収し、培養プレートに再び播種し、その後生着し、増殖している細胞を毛包幹細胞として以下の試験に用いた。
(Experimental example 1) Evaluation of the proliferation-promoting effect of Japanese pepper extract on hair follicle stem cells (1) Cultivation of human hair follicle stem cells The tissue containing After washing with PBS(-), treatment with trypsin (manufactured by BD Biosciences) was performed. Cells were then isolated and collected using a cell strainer (manufactured by FALCON). The collected cells were seeded on a culture plate and maintained until confluent using KG2 medium (manufactured by KURABO). The confluent cells were collected and reseeded on the culture plate, and then engrafted and proliferating cells were used as hair follicle stem cells in the following tests.
(2)サンショウの抽出物の毛包幹細胞に対する増殖促進活性の評価
毛包幹細胞にサンショウの抽出物を作用させ、サンショウの抽出物が毛包幹細胞の増殖にどのように関わっているかを評価した。KG2培地(KURABO社製)にて培養した毛包幹細胞を24ウェルの培養プレートに1×104個ずつ播種し、被験物質(製造例1~8のサンショウの抽出物)を最終濃度が1000μg/mlとなるように添加し、3日間培養を行った。
(2) Evaluating the proliferation-promoting activity of Japanese pepper extract on hair follicle stem cells Applying Japanese pepper extract to hair follicle stem cells to determine how the Japanese pepper extract is involved in the proliferation of hair follicle stem cells. evaluated. 1×10 4 hair follicle stem cells cultured in KG2 medium (manufactured by KURABO) were seeded in a 24-well culture plate, and the test substance (extract of Japanese pepper of Production Examples 1 to 8) was added to a final concentration of 1000 μg. /ml, and cultured for 3 days.
3日後の毛包幹細胞の細胞増殖率をMTTアッセイにより検出した。MTTアッセイは市販のMTTアッセイキット(コスモバイオ社製)を用い、添付されているプロトコルに従って行った。被験物質未添加時の総細胞数をコントロールとし、コントロールを100(%)とした場合の、被験物質添加時の細胞数の増減(%)を算出し、幹細胞増殖促進効果の評価を行った。これらの試験結果を以下の表1に示す。 The cell proliferation rate of hair follicle stem cells after 3 days was detected by MTT assay. MTT assay was performed using a commercially available MTT assay kit (manufactured by Cosmo Bio) according to the attached protocol. The total number of cells when no test substance was added was taken as a control, and the control was taken as 100 (%), and the change (%) in the number of cells when the test substance was added was calculated to evaluate the effect of promoting stem cell growth. The results of these tests are shown in Table 1 below.
表1に示すように、サンショウの抽出物(製造例1~8)には、毛包幹細胞に対していずれも顕著な増殖促進効果が認められた。なお、本実験例で用いた幹細胞以外に、胚性の幹細胞(ES細胞)についても同様な試験を行ったところ、顕著な幹細胞増殖促進効果が認められた。 As shown in Table 1, all of the extracts of Japanese pepper (Production Examples 1 to 8) were found to have a remarkable growth-promoting effect on hair follicle stem cells. In addition, when embryonic stem cells (ES cells) were also tested in the same manner as the stem cells used in this experimental example, a remarkable stem cell proliferation-promoting effect was observed.
(実験例2)サンショウの抽出物の毛包幹細胞に対する未分化状態維持効果の評価
毛包幹細胞にサンショウの抽出物を作用させ、サンショウの抽出物が毛包幹細胞の未分化性にどのように関わっているかを評価した。KG2培地(KURABO社製)にて培養した毛包幹細胞を24ウェルの培養プレートに1×104個ずつ播種し、被験物質(製造例1~8のサンショウの抽出物)を最終濃度が1000μg/mlとなるように添加して培養し、サンショウの抽出物の添加3日後の毛包幹細胞を回収し、毛包幹細胞の未分化性をKRT15(Keratin, type I cytoskeletal 15)の遺伝子発現量を指標に解析した。
(Experimental Example 2) Evaluation of the effect of extract of Japanese pepper on hair follicle stem cells to maintain an undifferentiated state The extract of Japanese pepper was applied to hair follicle stem cells to determine how the extract of Japanese pepper affects the undifferentiated state of hair follicle stem cells. and how they are involved. 1×10 4 hair follicle stem cells cultured in KG2 medium (manufactured by KURABO) were seeded in a 24-well culture plate, and the test substance (extract of Japanese pepper of Production Examples 1 to 8) was added to a final concentration of 1000 μg. 3 days after the addition of the extract of Japanese pepper, the hair follicle stem cells were collected. was analyzed as an index.
KRT15の遺伝子発現解析は次の通り行った。サンショウの抽出物添加後の毛包幹細胞をPBS(-)にて2回洗浄した後、Trizol Reagent(Invitrogen社製)によって該細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、下記プライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、KRT15の遺伝子発現量を測定した。その他の操作は定められた方法に従って実施した。 Gene expression analysis of KRT15 was performed as follows. The hair follicle stem cells after addition of the extract of Japanese pepper were washed twice with PBS(-), and then RNA was extracted from the cells with Trizol Reagent (manufactured by Invitrogen). After reverse transcription of the extracted RNA into cDNA using a 2-STEP real-time PCR kit (manufactured by Applied Biosystems), real-time PCR (95°C: 15 sec. , 60°C: 30 seconds, 40 cycles), and the gene expression level of KRT15 was measured. Other operations were carried out according to prescribed methods.
KRT15(毛包幹細胞未分化マーカー)用プライマーセット:
5'- GATGCTGCTTGACATAAAGACACG-3' (配列番号1)
5'- ACCTGTCCATCCACTGACTCTTC-3' (配列番号2)
18srRNA(内部標準)用プライマーセット:
5'-CCGAGCCGCCTGGATAC-3' (配列番号3)
5'-CAGTTCCGAAAACCAACAAAATAGA-3'(配列番号4)
Primer set for KRT15 (hair follicle stem cell undifferentiated marker):
5'-GATGCTGCTTGACATAAAGACACG-3' (SEQ ID NO: 1)
5'- ACCTGTCCATCCACTGACTCTTC-3' (SEQ ID NO: 2)
Primer set for 18srRNA (internal standard):
5'-CCGAGCCGCCTGGATAC-3' (SEQ ID NO: 3)
5'-CAGTTCCGAAAACCAACAAAATAGA-3' (SEQ ID NO: 4)
毛包幹細胞の未分化状態維持効果は、培養開始時の毛包幹細胞におけるKRT15のmRNAの発現量を内部標準である18s ribosomal RNA(18srRNA)の発現量に対する割合として算出したKRT15遺伝子相対発現量(KRT15遺伝子発現量/18srRNA遺伝子発現量)の値を100%未分化状態とし、これに対し、培養3日後の毛包幹細胞におけるKRT15の遺伝子相対発現量の値を算出し、評価した。これらの試験結果を以下の表2に示す。 The effect of maintaining the undifferentiated state of hair follicle stem cells was calculated as the relative expression level of KRT15 gene ( KRT15 gene expression level/18srRNA gene expression level) was defined as 100% undifferentiated state, and the relative expression level of KRT15 gene in hair follicle stem cells after 3 days of culture was calculated and evaluated. The results of these tests are shown in Table 2 below.
表2に示すように、サンショウの抽出物(製造例1~8)には、毛包幹細胞に対していずれも顕著な未分化状態維持効果が認められた。なお、本実験例で用いた幹細胞以外に、胚性の幹細胞(ES細胞)についても同様な試験を行ったところ、顕著な幹細胞未分化状態維持効果が認められた。 As shown in Table 2, all of the extracts of Japanese pepper (Production Examples 1 to 8) were found to have a remarkable effect of maintaining an undifferentiated state on hair follicle stem cells. In addition, when embryonic stem cells (ES cells) were also tested in the same manner as the stem cells used in this experimental example, a remarkable effect of maintaining an undifferentiated state of stem cells was observed.
以上の各実験例に示すように、サンショウの抽出物を幹細胞に適用することで、従来の技術に比べて、簡便且つ効率的に、未分化状態を維持させたまま幹細胞の増殖を促進させることが可能になった。 As shown in each of the above experimental examples, the application of the extract of Japanese pepper to stem cells promotes the proliferation of stem cells while maintaining their undifferentiated state more easily and efficiently than conventional techniques. became possible.
本発明の活用例として、再生医療や再生美容への応用が期待される。例えば、本発明を利用することで、再生医療や再生美容に用いる未分化状態の幹細胞を簡便に効率良く調製することが可能となる。さらに、幹細胞の移植後又は組織に存在する幹細胞に対して、本発明に係るサンショウの抽出物を、直接的に注入するか又は経口投与、塗布、貼付等により適用することで、該幹細胞を、未分化状態を維持させたまま増殖させることが可能である。
すなわち、本発明は、再生医療や再生美容における、幹細胞の製造方法及び/又は幹細胞の未分化状態維持剤又は増殖促進剤としての利用が可能である。
As an application example of the present invention, application to regenerative medicine and regenerative beauty is expected. For example, by using the present invention, it is possible to easily and efficiently prepare undifferentiated stem cells for use in regenerative medicine and regenerative cosmetics. Furthermore, the extract of Japanese pepper according to the present invention can be directly injected into stem cells after transplantation of stem cells or existing in tissues, or applied by oral administration, application, patching, etc. , it is possible to proliferate while maintaining an undifferentiated state.
That is, the present invention can be used as a method for producing stem cells and/or an agent for maintaining an undifferentiated state or promoting growth of stem cells in regenerative medicine and regenerative cosmetics.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018225425A JP7214191B2 (en) | 2018-11-30 | 2018-11-30 | Stem cell undifferentiated state maintenance agent and growth promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018225425A JP7214191B2 (en) | 2018-11-30 | 2018-11-30 | Stem cell undifferentiated state maintenance agent and growth promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020080821A JP2020080821A (en) | 2020-06-04 |
JP7214191B2 true JP7214191B2 (en) | 2023-01-30 |
Family
ID=70904469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018225425A Active JP7214191B2 (en) | 2018-11-30 | 2018-11-30 | Stem cell undifferentiated state maintenance agent and growth promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7214191B2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003306438A (en) | 2002-02-18 | 2003-10-28 | Shiseido Co Ltd | Chemokine expression inhibitor |
JP2018140950A (en) | 2017-02-27 | 2018-09-13 | 株式会社吉野家ホールディングス | Tie 2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalization agent, blood vessel stabilizer, pharmaceutical composition, composition for food and beverage, and food and drink |
-
2018
- 2018-11-30 JP JP2018225425A patent/JP7214191B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003306438A (en) | 2002-02-18 | 2003-10-28 | Shiseido Co Ltd | Chemokine expression inhibitor |
JP2018140950A (en) | 2017-02-27 | 2018-09-13 | 株式会社吉野家ホールディングス | Tie 2 activator, angiogenesis inhibitor, blood vessel maturation agent, blood vessel normalization agent, blood vessel stabilizer, pharmaceutical composition, composition for food and beverage, and food and drink |
Non-Patent Citations (7)
Title |
---|
Environmental Toxicology,2017年03月26日,Vol. 32,p. 2133-2143,DOI: 10.1002/tox.22426 |
IRYO, 2000, Vol.54, No.2, pp.73-78 |
Korean J. Plant Res. 29(5):620-624(2016),検索日:2022年8月24日、インターネット<URL: http://dx.doi.org/10.7732/kjpr.2016.29.5.620> |
NATURE CELL BIOLOGY, VOLUME 16, NUMBER 2, 2014, pp.179-192, DOI: 10.1038/ncb2903 |
大石 健介、Wnt シグナルに作用する生物活性天然物の探索、2015年、千葉大学,検索日:2022年8月24日、インターネット<URL: http://opac.ll.chiba-u.jp/da/curator/900119315/POA_0001.pdf> |
科学研究費助成事業、研究成果報告書、Wnt/βカテニン経路の幹細胞性維持・分化誘導機能に関するゲノムワイド研究、2015年,検索日:2022年8月24日、インターネット<URL: https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-25670851/25670851seika.pdf> |
第117回日本医学会シンポジウム記録集、2000, pp.58-66,検索日:2022年8月24日、インターネット<URL: https://jams.med.or.jp/event/doc/117058.pdf> |
Also Published As
Publication number | Publication date |
---|---|
JP2020080821A (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6535505B2 (en) | An agent for maintaining undifferentiated state of stem cells and an agent for promoting proliferation using the extract of Mannengtake mushroom | |
JP6843425B2 (en) | Stem cell undifferentiated state maintainer and growth promoter | |
JP6583679B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter using yeast extract | |
JP6571494B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter using Ainu Wakame | |
JP6697252B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP6411778B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP7214191B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP6468895B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP7202610B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
CN107075474B (en) | Agent for maintaining undifferentiated state of stem cells and agent for promoting proliferation of stem cells | |
JP7454215B2 (en) | Stem cell proliferation promoter | |
JP6587899B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP6649050B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP7178087B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP2019094268A (en) | Undifferentiated state maintenance agent for hair follicle stem cells | |
JP6840376B2 (en) | Stem cell undifferentiated state maintainer and growth promoter | |
JP6615589B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
JP6877014B2 (en) | Stem cell undifferentiated state maintainer and growth promoter | |
JP6529791B2 (en) | Agent for maintaining undifferentiated state of stem cells and growth promoter | |
JP7287653B2 (en) | Proliferation promoter for stem cells | |
JP6844829B2 (en) | Stem cell undifferentiated state maintainer and growth promoter | |
JP6763604B2 (en) | Stem cell undifferentiated state maintainer and growth promoter | |
JP7319611B2 (en) | Proliferation promoter for stem cells | |
JP2024038890A (en) | Function enhancer for exosome | |
JP2024151772A (en) | Stem cell proliferation promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211028 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221220 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7214191 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |